OSL GROUP (00863) issued a profit warning, expecting a net loss of approximately HK$370 million to HK$430 million for the year 2025, a reversal from profit to loss compared to the previous year.
OSL Group (00863) announced that the group expects a net loss from continuing operations of approximately HK$370-430 million for the 2025 financial year (ending December 31, 2025), compared to a profit of approximately HK$55 million from continuing operations for the financial year ending December 31, 2024. The reason for the expected net loss is due to significant investments made by the group to establish a solid foundation for future growth. Despite the anticipated net loss, the group's business continues to demonstrate strong growth momentum.
OSL GROUP (00863) announced that it is expected to incur a net loss in its ongoing business operations in the 2025 financial year (ending on December 31, 2025) ranging from approximately HK$370 million to HK$430 million, while it achieved a surplus of approximately HK$55 million in its ongoing business operations in the financial year ending December 31, 2024 (2024 financial year), due to significant investments made by the Group to establish a solid foundation for future growth. Despite the expected net loss, the Group's business continues to show strong growth momentum:
(i)
Expected revenue from digital assets and blockchain platform business in the 2025 financial year (IFRS revenue) is expected to range between HK$450 million to HK$530 million, representing an increase of 20.0% to 41.3% from the IFRS revenue of approximately HK$375 million in the 2024 financial year; and
(ii)
Expected revenue from adjusted digital assets and blockchain platform business in the 2025 financial year (adjusted non-IFRS revenue) is expected to range between HK$490 million to HK$570 million, a significant increase of 129.0% to 166.4% from the adjusted non-IFRS revenue of approximately HK$214 million in the 2024 financial year, reflecting the continued growth of the Group's core business activities.
Related Articles

INSILICO (03696): AI-driven NLRP3 inhibitor ISM8969 clinical trial application approved by FDA Has "best-in-class" potential
.png)
Hydsoft Technology (301316.SZ) issued shares to purchase assets and raised funds for matching, the application documents have been accepted by the Shenzhen Stock Exchange.

Zhongjin: European and American trade relations under geopolitical disputes.
INSILICO (03696): AI-driven NLRP3 inhibitor ISM8969 clinical trial application approved by FDA Has "best-in-class" potential

Hydsoft Technology (301316.SZ) issued shares to purchase assets and raised funds for matching, the application documents have been accepted by the Shenzhen Stock Exchange.
.png)
Zhongjin: European and American trade relations under geopolitical disputes.

RECOMMEND

Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026

Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026

Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026


